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ABSTRACT 
 
Melanoma with unknown primary (MUP) accounts for approximately 1% to 8% of all melanomas and was 
described first in 1952. We report a case of a 95 year old male with a painless, progressively increasing swelling of 
the inguinal region, which on investigations came out to be malignant melanoma metastatic to inguinal nodes, 
without clinical or radiological evidence of a known primary. Metastatic melanoma is often confused with a variety 
of poorly differentiated carcinomas, sarcomas, and large cell lymphomas. Immunohistochemistry along with 
histopathology is important in the diagnosis and sub-classification of tumors. The importance of presenting this 
paper is to highlight the rare presence of malignant melanoma metastatic to lymph nodes with an unknown primary, 
and the role of immunohistochemistry in the diagnosis. 
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INTRODUCTION
Melanoma with unknown primary (MUP) accounts for 
approximately 1% to 8% of all melanomas and was 
described first in 1952.[1]The clinical presentation of 
MUP with nodal metastasis (American Joint Committee 
on Cancer stage III) is characterized by palpable 
lymphadenopathy without an apparent primary 
melanoma and without evidence of further metastatic 
disease.[2] 
Metastatic melanoma is often confused with a variety of 
poorly differentiated carcinomas, sarcomas, and large 
cell lymphomas and hence always needs to be considered 
in differential diagnosis of these malignant tumors. 
Accurate diagnosis is needed for treatment as well as 
prognosis. Immunohistochemistry along with 
histopathology is important in the diagnosis and sub-
classification of tumors.  
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In the pre-immunoperoxidase era, the only useful special 
stains in establishing the diagnosis were melanin stains 
such as the Fontana-Masson stain and the Warthin-Starry 
stain. These stains have been largely replaced by 
immunoperoxidase stains Many IHC markers, especially 
in lymphomas, also have a role in predicting the 
prognosis.[3] The panel of tumor markers, most 
commonly used for evaluation of melanoma includes 
HMB45,S-100 protein, CEA, EMA, Melan-A & 
Vimentin, an intermediate filament. 
The limitation of these stains is that some malignant 
melanomas are amelanotic, causing the stains to be 
negative.  
 
CASE HISTORY 
 
We report the case of a 96 yr old male who presented 
with a painless progressively increasing swelling in his 
left inguinal region for the past two months. There was 
no history of any cutaneous lesion, previous skin biopsy, 
urinary or bowel complaints, visual disturbances, chronic 
headache or seizures. On examination, there was a 4 x 
3cm lump in the left inguinal region. It had bosselated 
surface with bluish hue and limited side to side mobility. 
The rest of the examination including proctoscopy, 
colposcopy, otorhinological and ophthalmologic 
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examinations was unremarkable. FNAC from the mass 
revealed it to be a pleomorphic malignancy-?malignant 
melanoma(fig. 1). A diagnosis of pleomorphic 
malignancy-? malignant melanoma of the left inguinal 
lymph nodal region with an unknown primary was made 
and the patient was taken up for excision of tumour mass 
with complete ilioinguinal lymph node dissection. 
Intraoperatively, there was a lymph nodal mass 
measuring 3 x 2cm in the left superficial inguinal lymph 
nodal basin with multiple lymph nodes along the 
external iliac artery. Postoperatively, the patient had an 
unremarkable recovery. The HPE revealed it to be 
malignant melanoma (Melan A & HMB 45 positive) 
metastatic to inguinal lymph nodes. Grossly it was a 
circumscribed mass of size 3x2 cm, Cut surface- gray 
white. On microscopy section showed thin fibrous 
capsule of lymph node, underneath shows strip of normal 
lymphocytes and total effacement of lymph node 
architecture replaced by tumor tissue composed of large 
round and spindle cells with high N: C ratio, scanty 
cytoplasm, nuclear pleomorphism and prominent 
nucleoli. Cells arranged in sheets and nests (fig. 2). On 
immunohistochemistry the tumor cells show strong 
immunopositivity for vimentin and Melan A and focal 
immunoreactivity for S-100 protein and HMB 45.The 
tumor cells were immunonegative for pancytokeratin 
(fig. 3-7). 
 
 
Figure 1: Shows pleomorphic malignant cells having pleomorphic nuclei with prominent nucleoli(Pap 100X) 
 
Figure 2: Shows large round and spindle cells with high N:C ratio, nuclear pleomorphism and prominent 
nucleoli (H&E 40X) 
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Figure 3: Shows Melan A positive 
 
Figure 4: Shows Vimentin positive 
 
Figure 5: Shows HMB45 focal positive 
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Figure 6: Shows S-100 Focal positive 
 
 
  
Figure 7: Shows Cytokeratin negative 
 
DISCUSSION 
 
Metastatic unknown primary occurs in less than 8% of 
all melanomas, with the axillary lymph nodal basin most 
commonly involved. Although the true etiology of an 
MUP is unknown, several explanations have been 
suggested and include 1) a concurrent, unrecognized 
melanoma; 2) a previously excised melanoma that was 
misdiagnosed either clinically or pathologically; 3) an 
antecedent, unrecognized, spontaneously regressed 
primary melanoma; and 4) the de novo malignant 
transformation of an aberrant melanocyte within a lymph 
node.[4] One commonly accepted theory is that an 
unrecognized primary lesion has undergone spontaneous 
regression mediated by an endogenous immune 
response.[5] 
Metastatic melanoma should be considered in the 
differential diagnosis of all patients who present with a 
malignancy of unknown origin, particularly when lymph 
nodes are the primary presenting site. Metastatic 
melanoma is often confused with a variety of poorly 
differentiated carcinomas, sarcomas, and large cell 
lymphomas. Fine-needle aspiration or core biopsy of the 
lymph node lesion usually is adequate for tissue 
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diagnosis, but immunohistochemical studies (i.e., 
immunoreactivity for S-100, vimentin, and HMB-45) 
and electron microscopy studies looking for 
melanosomes or premelanosomes also may be obtained 
in the event of equivocal findings.[6] 
Immunohistochemistry along with histopathology is 
important in the diagnosis and sub-classification of 
tumors. According to Gibbs JF et al [7] definitive 
diagnosis should await permanent H&E sections and IH 
staining. Since the advent of reliable immunoperoxidase 
stains, the use of an initial screening panel of 
immunoperoxidase markers (eg, S-100, pancytokeratin, 
CD45) has become routine in poorly differentiated 
tumors to determine the cell lineage. This is followed by 
a second panel of immunoperoxidase markers to narrow 
the possibilities or confirm the diagnosis. The panel of 
tumor markers most commonly used for evaluation of 
melanoma includes HMB45, S-100 protein, CEA, EMA, 
Melan-A & Vimentin an intermediate filament. 
According to Lewis KD et al [3] the most common 
mistake made in undifferentiated tumors is to use only a 
single marker to diagnose malignant melanoma. This 
approach is fraught with potential errors since malignant 
melanomas can occasionally express unexpected 
markers. Poorly differentiated tumors need to express at 
least two melanoma immunoperoxidase markers (ie, S-
100, KBA-62, HMB-45, or melanin-A) before a firm 
diagnosis of malignant melanoma is rendered. DJ 
Karimipour et al [8] reported the sensitivities of S-100, 
HMB-45, and Melan-A to 97%, 75%, and 96% 
respectively. 
 
CONCLUSION 
 
Malignant melanoma with unknown primary is a rare 
entity that should be considered in the differential 
diagnosis of all patients presenting with malignant 
lymphadenopathy with an unknown primary. Poorly 
differentiated malignancies that are suspicious for 
malignant melanoma are best diagnosed by a screening 
panel of immunoperoxidase markers followed by a 
second panel to confirm the diagnosis.  
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